CRISPR Therapeutics AG
CRSP
$56.09
-$0.17-0.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -86.13% | -89.95% | 19.31% | 18.89% | 171.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -86.13% | -89.95% | 19.31% | 18.89% | 171.01% |
| Cost of Revenue | -12.20% | -16.75% | -9.54% | -12.54% | -11.77% |
| Gross Profit | -76.34% | -168.89% | 23.85% | 26.45% | 51.19% |
| SG&A Expenses | 3.57% | -4.18% | -11.77% | -19.38% | -25.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.22% | -15.14% | -9.84% | -13.49% | -13.84% |
| Operating Income | -58.86% | -109.66% | 21.54% | 25.12% | 46.83% |
| Income Before Tax | -77.66% | -140.62% | 34.38% | 37.90% | 59.20% |
| Income Tax Expenses | 73.30% | 24.20% | 145.74% | 134.02% | 187.72% |
| Earnings from Continuing Operations | -77.61% | -138.43% | 32.23% | 36.09% | 58.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.61% | -138.43% | 32.23% | 36.09% | 58.56% |
| EBIT | -58.86% | -109.66% | 21.54% | 25.12% | 46.83% |
| EBITDA | -63.16% | -120.67% | 22.29% | 25.97% | 48.19% |
| EPS Basic | -67.30% | -123.71% | 37.49% | 39.60% | 59.84% |
| Normalized Basic EPS | -67.36% | -125.77% | 39.50% | 41.31% | 60.46% |
| EPS Diluted | -65.52% | -121.12% | 36.73% | 39.02% | 59.41% |
| Normalized Diluted EPS | -65.95% | -123.12% | 39.00% | 40.89% | 60.12% |
| Average Basic Shares Outstanding | 6.74% | 6.48% | 5.11% | 3.72% | 2.38% |
| Average Diluted Shares Outstanding | 6.20% | 5.94% | 5.63% | 4.24% | 2.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |